Morgan Stanley’s ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share ATIP.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-24
Closed 8246
2021
Q4
$0 Hold
24
﹤0.01% 8234
2021
Q3
$0 Hold
24
﹤0.01% 8100
2021
Q2
$0 Buy
+24
New +$54 ﹤0.01% 7849

Other funds holding ATIP.WS

Morgan Stanley's ATIP.WS Position: Q1 2022 in Review

Morgan Stanley sold out of ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share (ATIP.WS) in Q1 2022, closing a stake of 24 shares.

Morgan Stanley first reported a position in ATIP.WS in Q2 2021 and held it in 3 quarters. The position peaked at $0 in Q4 2021. 18 funds tracked by Wall St. Rank hold ATIP.WS as of Q1 2022.

  • Morgan Stanley reported no remaining ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share position as of Q1 2022 after selling out during the quarter.
  • Morgan Stanley sold 24 ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share shares in Q1 2022.
  • Morgan Stanley first reported a position in ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share in Q2 2021 and held it in 3 quarters.
  • Morgan Stanley's ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share position peaked at $0 in Q4 2021.
  • 18 funds tracked by Wall St. Rank held ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share as of Q1 2022.

Based on Morgan Stanley's 13F filing for Q1 2022, filed 13 May 2022.